Sugi Predict

Sugi Predict / Compounds / SCHEMBL3255010

SCHEMBL3255010

SCHEMBL3255010

Clc1cccc2c1NO[N]2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR5A P47898 1/20 0.35
▸ NSD2 O96028 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ DAO P14920 1/20 0.34
▸ CES1 P23141 1/20 0.34
▸ AHR P35869 3/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ PSMB8 P28062 1/20 0.33
▸ TSHR P16473 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ IDO1 P14902 3/20 0.32
▸ MAPT P10636 1/20 0.32
▸ NOS1 P29475 2/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA4 P22748 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4753134 0.63 CES1 (0.44) HTR5ANSD2BCHEDAOCES1
SCHEMBL4245297 0.62 CYP1A2 (0.40) HTR5ANSD2BCHEDAOCES1
SCHEMBL3698938 0.60 MAPT (0.38) HTR5ANSD2BCHEDAOCES1
SCHEMBL2724592 0.57 ALOX5 (0.59) NSD2BCHEDAOCES1AHR
SCHEMBL18920567 0.56 CYP1A2 (0.43) CES1CYP1A2CYP2A6TSHRLMNA
SCHEMBL12188521 0.56 CYP1A2 (0.43) AHRCYP1A2CYP2A6PSMB8TSHR
SCHEMBL23239 0.54 — —
SCHEMBL3991309 0.54 TSHR (0.61) CYP1A2CYP2A6TSHRLMNAIDO1
SCHEMBL2471569 0.54 TSHR (0.57) CES1CYP1A2CYP2A6TSHRLMNA
SCHEMBL9579668 0.54 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 — — EP claimed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 — — US claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 — — US claimed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 — — EP claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 — — US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 — — US claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 — — EP claimed
EP-1461325-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 — — EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 — — US claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US claimed
WO-2003043999-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 — — WO claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 — — WO claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 — — WO claimed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 — — EP claimed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 HTR5A 1401/4885NSD2 3070/4885BCHE 1011/4885
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HTR5A 1079/4885NSD2 3361/4885BCHE 699/4885
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HTR5A 1706/4885NSD2 2404/4885BCHE 560/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HTR5A 1657/4885NSD2 3131/4885BCHE 1142/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HTR5A 1755/4885NSD2 2387/4885BCHE 582/4885
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HTR5A 1755/4885NSD2 2387/4885BCHE 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.